$TKNO
Alpha Teknova, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024036624 Filed on March 27, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $9.290M $7.867M $36.68M
YoY Change 1.85% -0.3% -11.43%
Cost Of Revenue $7.081M $6.532M $26.39M
YoY Change 5.72% 12.99% 10.21%
Gross Profit $2.209M $1.335M $10.30M
YoY Change -8.83% -36.73% -41.08%
Gross Profit Margin 23.78% 16.97% 28.07%
Selling, General & Admin $9.048M $8.425M $34.78M
YoY Change -6.61% -15.76% -7.13%
% of Gross Profit 409.6% 631.09% 337.8%
Research & Development $860.0K $1.311M $5.567M
YoY Change -38.35% -29.89% -28.05%
% of Gross Profit 38.93% 98.2% 54.07%
Depreciation & Amortization $1.636M $1.611M $5.660M
YoY Change 44.78% 80.4% 78.83%
% of Gross Profit 74.06% 120.67% 54.97%
Operating Expenses $10.20M $10.02M $41.49M
YoY Change -10.33% -17.55% -10.44%
Operating Profit -$7.986M -$8.689M -$31.20M
YoY Change -10.73% -13.53% 8.11%
Interest Expense -$145.0K -$440.0K -$1.446M
YoY Change -255.91% -443.75% -778.87%
% of Operating Profit
Other Income/Expense, Net -$145.0K $338.0K $755.0K
YoY Change -230.63% 1678.95% 1272.73%
Pretax Income -$8.131M -$10.96M -$37.08M
YoY Change -7.97% -22.21% -24.93%
Income Tax -$34.00K -$304.0K -$298.0K
% Of Pretax Income
Net Earnings -$8.097M -$10.66M -$36.78M
YoY Change -8.17% -19.84% -22.52%
Net Earnings / Revenue -87.16% -135.45% -100.26%
Basic Earnings Per Share -$0.20 -$1.16
Diluted Earnings Per Share -$0.20 -$0.26 -$1.16
COMMON SHARES
Basic Shares Outstanding 40.82M 40.73M 31.82M
Diluted Shares Outstanding 40.80M 31.82M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.60M $28.59M $28.59M
YoY Change -28.53% -32.3% -32.3%
Cash & Equivalents $21.60M $28.59M $28.59M
Short-Term Investments
Other Short-Term Assets $1.460M $1.524M $1.524M
YoY Change -40.79% -35.8% -35.8%
Inventory $11.21M $11.59M $11.59M
Prepaid Expenses
Receivables $4.560M $3.948M $3.948M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $38.82M $45.66M $45.66M
YoY Change -21.78% -25.32% -25.32%
LONG-TERM ASSETS
Property, Plant & Equipment $48.91M $66.84M $66.84M
YoY Change -8.98% -6.28% -6.28%
Goodwill
YoY Change
Intangibles $13.95M $14.24M
YoY Change -19.21% -18.89%
Long-Term Investments
YoY Change
Other Assets $1.735M $1.852M $1.852M
YoY Change -19.3% -17.76% -17.76%
Total Long-Term Assets $81.99M $82.93M $82.93M
YoY Change -10.28% -8.99% -8.99%
TOTAL ASSETS
Total Short-Term Assets $38.82M $45.66M $45.66M
Total Long-Term Assets $81.99M $82.93M $82.93M
Total Assets $120.8M $128.6M $128.6M
YoY Change -14.33% -15.55% -15.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.543M $1.493M $1.493M
YoY Change -18.14% -39.04% -39.04%
Accrued Expenses $3.574M $7.382M $7.382M
YoY Change -24.88% -12.39% -12.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $7.039M $8.875M $8.875M
YoY Change -18.66% -18.39% -18.39%
LONG-TERM LIABILITIES
Long-Term Debt $13.18M $13.25M $13.25M
YoY Change -40.2% -39.7% -39.7%
Other Long-Term Liabilities $16.34M $15.51M $15.51M
YoY Change -4.12% -15.28% -15.28%
Total Long-Term Liabilities $13.18M $28.76M $28.76M
YoY Change -66.28% -28.6% -28.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.039M $8.875M $8.875M
Total Long-Term Liabilities $13.18M $28.76M $28.76M
Total Liabilities $37.44M $38.55M $38.55M
YoY Change -23.49% -26.4% -26.4%
SHAREHOLDERS EQUITY
Retained Earnings -$99.90M -$91.80M
YoY Change 56.58% 66.91%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $83.38M $90.04M $90.04M
YoY Change
Total Liabilities & Shareholders Equity $120.8M $128.6M $128.6M
YoY Change -14.33% -15.55% -15.55%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$8.097M -$10.66M -$36.78M
YoY Change -8.17% -19.84% -22.52%
Depreciation, Depletion And Amortization $1.636M $1.611M $5.660M
YoY Change 44.78% 80.4% 78.83%
Cash From Operating Activities -$6.558M -$2.782M -$18.70M
YoY Change -14.65% -65.35% -31.74%
INVESTING ACTIVITIES
Capital Expenditures $112.0K $312.0K $7.934M
YoY Change -97.4% -93.4% -71.81%
Acquisitions
YoY Change
Other Investing Activities $125.0K $197.0K $197.0K
YoY Change
Cash From Investing Activities $13.00K -$115.0K -$7.737M
YoY Change -100.3% -97.57% -72.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $328.0K
YoY Change -25.28%
Debt Paid & Issued, Net $10.00M
YoY Change
Cash From Financing Activities -343.0K -621.0K 12.80M
YoY Change 1272.0% -112.08% 24.66%
NET CHANGE
Cash From Operating Activities -6.558M -2.782M -18.70M
Cash From Investing Activities 13.00K -115.0K -7.737M
Cash From Financing Activities -343.0K -621.0K 12.80M
Net Change In Cash -6.888M -3.518M -13.64M
YoY Change -42.7% -53.83% -69.87%
FREE CASH FLOW
Cash From Operating Activities -$6.558M -$2.782M -$18.70M
Capital Expenditures $112.0K $312.0K $7.934M
Free Cash Flow -$6.670M -$3.094M -$26.64M
YoY Change -44.4% -75.75% -52.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001850902
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40538
CY2023 dei Entity Registrant Name
EntityRegistrantName
ALPHA TEKNOVA, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3368109
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2451 Bert Dr.
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Hollister
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95023
CY2023 dei City Area Code
CityAreaCode
831
CY2023 dei Local Phone Number
LocalPhoneNumber
637-1100
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
CY2023 dei Trading Symbol
TradingSymbol
TKNO
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
18703398
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40823387
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Jose, CA
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36684000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41420000
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26388000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23944000
CY2023 us-gaap Gross Profit
GrossProfit
10296000
CY2022 us-gaap Gross Profit
GrossProfit
17476000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5567000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7737000
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9330000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9151000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25450000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28298000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1148000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1148000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
16613000
CY2023 tkno Tradename Impairment Loss
TradenameImpairmentLoss
2169000
CY2022 tkno Tradename Impairment Loss
TradenameImpairmentLoss
0
CY2023 tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
2195000
CY2022 tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
4188000
CY2023 us-gaap Operating Expenses
OperatingExpenses
45859000
CY2022 us-gaap Operating Expenses
OperatingExpenses
67135000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-35563000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-49659000
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-833000
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
213000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
142000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
55000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-824000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1515000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
268000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37078000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49391000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-298000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1923000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-36780000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-47468000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.69
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31819776
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31819776
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28083563
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28083563
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28484000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42236000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
20000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
22000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3948000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4261000
CY2023Q4 us-gaap Inventory Net
InventoryNet
11594000
CY2022Q4 us-gaap Inventory Net
InventoryNet
12247000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
22000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1634000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2374000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
45660000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
61140000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50364000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51577000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16472000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19736000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14239000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17556000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1852000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2252000
CY2023Q4 us-gaap Assets
Assets
128587000
CY2022Q4 us-gaap Assets
Assets
152261000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1493000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2449000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5579000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6203000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1803000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2223000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8875000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10875000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
919000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1223000
CY2023Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
102000
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
191000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
13251000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
21976000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15404000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18111000
CY2023Q4 us-gaap Liabilities
Liabilities
38551000
CY2022Q4 us-gaap Liabilities
Liabilities
52376000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40793848
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40793848
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28179423
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28179423
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
181822000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
154891000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91786000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55006000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
90036000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
99885000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128587000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152261000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
143203000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3711000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
145000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
294000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-47468000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
99885000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4137000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
252000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22466000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-36780000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
90036000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-36780000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-47468000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
21000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
25000
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
323000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
697000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5660000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3165000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
4137000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3711000
CY2023 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-304000
CY2022 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1930000
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
498000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
278000
CY2023 tkno Non Cash Lease Expense
NonCashLeaseExpense
137000
CY2022 tkno Non Cash Lease Expense
NonCashLeaseExpense
329000
CY2023 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-57000
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-326000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
16613000
CY2023 tkno Tradename Impairment Loss
TradenameImpairmentLoss
2169000
CY2022 tkno Tradename Impairment Loss
TradenameImpairmentLoss
0
CY2023 tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
2195000
CY2022 tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
4188000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-824000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-292000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-380000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-330000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7550000
CY2023 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-22000
CY2022 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-1166000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-131000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-64000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-400000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
2072000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-773000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
572000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1936000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
188000
CY2023 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-89000
CY2022 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-82000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18814000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27400000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
197000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7934000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28149000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7737000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28149000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22503000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10000000
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2023 tkno Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
1004000
CY2022 tkno Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
0
CY2023 tkno Repayment Of Financed Insurance Premiums
RepaymentOfFinancedInsurancePremiums
594000
CY2022 tkno Repayment Of Financed Insurance Premiums
RepaymentOfFinancedInsurancePremiums
0
CY2023 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10135000
CY2023 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
47000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
172000
CY2023 tkno Payment Of Exit Fee Costs
PaymentOfExitFeeCosts
0
CY2022 tkno Payment Of Exit Fee Costs
PaymentOfExitFeeCosts
135000
CY2023 tkno Payment Of At The Market Facility Costs
PaymentOfAtTheMarketFacilityCosts
395000
CY2022 tkno Payment Of At The Market Facility Costs
PaymentOfAtTheMarketFacilityCosts
0
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
145000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
252000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
294000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12799000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10267000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13752000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45282000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42236000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87518000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28484000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42236000
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1749000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
101000
CY2023 tkno Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
37000
CY2022 tkno Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
0
CY2023 tkno Capitalized Property Plant And Equipment Included In Accounts Payable And Accrued Liabilities
CapitalizedPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
51000
CY2022 tkno Capitalized Property Plant And Equipment Included In Accounts Payable And Accrued Liabilities
CapitalizedPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
2237000
CY2023 tkno Recognition Of Operating Right Of Use Lease Asset
RecognitionOfOperatingRightOfUseLeaseAsset
-1137000
CY2022 tkno Recognition Of Operating Right Of Use Lease Asset
RecognitionOfOperatingRightOfUseLeaseAsset
22094000
CY2023 tkno Recognition Of Operating Lease Liabilities
RecognitionOfOperatingLeaseLiabilities
-1193000
CY2022 tkno Recognition Of Operating Lease Liabilities
RecognitionOfOperatingLeaseLiabilities
22363000
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Nature of the Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alpha Teknova, Inc. (referred to herein as the Company or Teknova), produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Product offerings include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions, with catalog and custom, made-to-order products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Teknova manufactures its products at its Hollister, California headquarters and stocks inventory of raw materials, components, and finished goods at that location. The Company ships products directly from its warehouse in Hollister, California.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concurrent Registered Direct Offering and Private Placements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 15, 2023, the Company entered into a securities purchase agreement (the Registered Direct Purchase Agreement) in connection with a registered direct offering (the Registered Direct Offering) with certain accredited investors and qualified institutional buyers. On September 15, 2023, the Company also entered into a securities purchase agreement (the PIPE Purchase Agreement and, together with the Registered Direct Purchase Agreement, the Purchase Agreements) and a registration rights agreement (the Registration Rights Agreement) in connection with a concurrent private placement (the PIPE Private Placement) with certain accredited investors and qualified institutional buyers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Registered Direct Purchase Agreement, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,086,485</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company’s common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value per share (the Common Stock) at an offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Pursuant to the PIPE Purchase Agreement, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,299,993</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock (the PIPE Shares), at the same offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s controlling stockholder, Telegraph Hill Partners Management Company LLC, through its affiliates Telegraph Hill Partners IV, L.P. and THP IV Affiliates Fund, LLC, the Company’s President and Chief Executive Officer and a member of its board of directors, Stephen Gunstream, the Company’s Chief Financial Officer, Matthew Lowell, and the Company’</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s General Counsel and Chief Compliance Officer, Damon Terrill, and the Mackowski Family Trust, which is affiliated with J. Matthew Mackowski, a member of the Company’s board of directors, participated in the PIPE Private Placement and purchased an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,054,052</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock on the same terms as the other investors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company received aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.915</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Registered Direct Offering and PIPE Private Placement (collectively, the Offerings), before deducting offering expenses related to the Offerings. As of December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of costs directly related to these Offerings were included as a reduction to additional paid-in capital on the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Offerings closed on September 19, 2023.</span></p>
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22915000
CY2023 tkno Offering Expenses
OfferingExpenses
400000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-36800000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91800000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
12100000
CY2023Q4 tkno Working Captial
WorkingCaptial
36800000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28500000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Teknova’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places its cash with high-quality banking institutions. At times, the Company’s cash balances may exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Teknova’s cash equivalents consist primarily of money market funds and U.S. Treasuries. Teknova extends credit to customers based on its evaluation of the customer’</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s financial condition and routinely communicates with its customers regarding payments. The Company has a history of limited write-offs, and therefore believes that its accounts receivable credit risk exposure is low. For information regarding the Company’s significant customers and suppliers, see Note 4. Concentrations of Risk.</span></p>
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023Q4 tkno Capitalized Software Implementation Costs
CapitalizedSoftwareImplementationCosts
1800000
CY2022Q4 tkno Capitalized Software Implementation Costs
CapitalizedSoftwareImplementationCosts
2200000
CY2023 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
400000
CY2022 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
100000
CY2023 tkno Reduction In Workforce Policytext Blocks
ReductionInWorkforcePolicytextBlocks
<p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reduction in Workforce</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 1, 2023, the Company carried out a reduction in workforce of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> positions, aimed at reducing operating expenses. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2023, in general and administrative expenses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the accompanying financial statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 tkno Number Of Product Categories
NumberOfProductCategories
2
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36684000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41420000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36684000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41420000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8573000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8368000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
47000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
186000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2974000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3693000
CY2023Q4 us-gaap Inventory Net
InventoryNet
11594000
CY2022Q4 us-gaap Inventory Net
InventoryNet
12247000
CY2023Q4 tkno Property Plant And Equipment After Depreciation
PropertyPlantAndEquipmentAfterDepreciation
55888000
CY2022Q4 tkno Property Plant And Equipment After Depreciation
PropertyPlantAndEquipmentAfterDepreciation
32383000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7528000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4520000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
48360000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27863000
CY2023Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2004000
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
23714000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50364000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51577000
CY2023 us-gaap Depreciation
Depreciation
4500000
CY2022 us-gaap Depreciation
Depreciation
2000000
CY2023 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
900000
CY2022 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
1600000
CY2023 tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
2200000
CY2022 tkno Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
4200000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
2900000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
3200000
CY2023 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
2800000
CY2022 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
2800000
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y10M24D
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2601000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2354000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2413000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2416000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2265000
CY2023Q4 tkno Lesseeoperatingleaseliabilitytobepaidafteryearfive
Lesseeoperatingleaseliabilitytobepaidafteryearfive
9652000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
21701000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4494000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
17207000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
19930000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5691000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14239000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
22099000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4543000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17556000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000
CY2023 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P3Y
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1148000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1148000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1148000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
45000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3489000
CY2023 tkno Tradename Impairment Loss
TradenameImpairmentLoss
2200000
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill Fair Value Disclosure
IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
10800000
CY2022 tkno Tradename Impairment Loss
TradenameImpairmentLoss
0
CY2023 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
16600000
CY2023 tkno Weighted Average Cost Of Capital
WeightedAverageCostOfCapital
0.18
CY2023 tkno Implied Control Premium
ImpliedControlPremium
0.25
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3826000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2796000
CY2023Q4 tkno Accrued Liabilities Property Plant And Equipment Current
AccruedLiabilitiesPropertyPlantAndEquipmentCurrent
0
CY2022Q4 tkno Accrued Liabilities Property Plant And Equipment Current
AccruedLiabilitiesPropertyPlantAndEquipmentCurrent
1966000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
16000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
198000
CY2023Q4 tkno Insurance Premiums And Accrued Interest
InsurancePremiumsAndAccruedInterest
409000
CY2022Q4 tkno Insurance Premiums And Accrued Interest
InsurancePremiumsAndAccruedInterest
0
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
300000
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1028000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1243000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5579000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6203000
CY2023Q3 tkno Insurance Premiums Paid
InsurancePremiumsPaid
1200000
CY2023Q3 tkno Annual Interest Rate To Finance For Insurance Premiums
AnnualInterestRateToFinanceForInsurancePremiums
0.0774
CY2023 tkno Insurance Premiums Down Payment
InsurancePremiumsDownPayment
200000
CY2023 tkno Insurance Premiums Frequency Of Payments
InsurancePremiumsFrequencyOfPayments
600000
CY2023Q4 tkno Insurance Premiums And Accrued Interest
InsurancePremiumsAndAccruedInterest
400000
CY2022Q4 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
5000000
CY2021Q1 tkno Cash Received Under The Term Loan
CashReceivedUnderTheTermLoan
12000000
CY2022Q4 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
40135000
CY2022Q4 tkno Cash Received Under The Term Loan2
CashReceivedUnderTheTermLoan2
5135000
CY2022Q4 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
5000000
CY2023Q2 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
10000000
CY2023Q4 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
10000000
tkno Contingent Revenue
ContingentRevenue
15000000
CY2023 tkno Liquidity Line Of Credit
LiquidityLineOfCredit
10000000
CY2022Q4 tkno Cash Received Under The Term Loan3
CashReceivedUnderTheTermLoan3
5000000
CY2022Q2 us-gaap Line Of Credit Facility Description
LineOfCreditFacilityDescription
If any advance under the Term Loan was prepaid at any time, the prepayment fee was based on the amount being prepaid and an applicable percentage amount, such as 3%, 2%, or 1%, based on the date the prepayment was made after the closing date of the Term Loan.
CY2022Q2 tkno Term Loan Exit Fee Rate
TermLoanExitFeeRate
0.05
CY2022 tkno Net Revenue Requirement For The Financial Covenant
NetRevenueRequirementForTheFinancialCovenant
42500000
CY2023Q1 us-gaap Line Of Credit Facility Description
LineOfCreditFacilityDescription
removed the increase in the minimum cash covenant from $10.0 million to $15.0 million on the $10.0 million in borrowings in the first half of 2024, and added the $10.0 million minimum cash covenant requirement throughout the remaining term of the Credit Agreement
CY2023Q3 us-gaap Debt Instrument Covenant Description
DebtInstrumentCovenantDescription
No. 4 also removed those requirements for the periods ending January 31, 2026 through March 31, 2027, instead requiring that for each applicable twelve-month period ending after December 31, 2025, the Company’s minimum net revenue requirement was to be determined by MidCap in its reasonable discretion in consultation with the Company’s senior management and based on financial statements and projections delivered to MidCap in accordance with the financial reporting requirements in Amendment No. 4, so long as the minimum net revenue requirements for those periods shall not be less than the greater of (x) the applicable minimum net revenue requirement for the twelve-month period ending on the last day of the immediately preceding month and (y) $50.0
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
12135000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
22135000
CY2023Q4 tkno Debt Instrument Cumulative Accretion Of Exit Fee
DebtInstrumentCumulativeAccretionOfExitFee
1261000
CY2022Q4 tkno Debt Instrument Cumulative Accretion Of Exit Fee
DebtInstrumentCumulativeAccretionOfExitFee
161000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
145000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
320000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
13251000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
21976000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3539000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6068000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2528000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12135000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4137000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3711000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.002
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.008
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.039
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
6000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
7000
CY2023 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
6000
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
7000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-25000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2055000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-279000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
125000
CY2023 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-304000
CY2022 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-1930000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-298000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1923000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.059
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.056
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.005
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.005
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.007
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.002
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.261
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.136
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
-0.09
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.002
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14184000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8005000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
803000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
552000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1823000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1008000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
880000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
275000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
131000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
321000
CY2023Q4 tkno Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
4599000
CY2022Q4 tkno Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
5435000
CY2023Q4 tkno Deferred Tax Asset Deferred Expense Capitalization Research And Development
DeferredTaxAssetDeferredExpenseCapitalizationResearchAndDevelopment
2304000
CY2022Q4 tkno Deferred Tax Asset Deferred Expense Capitalization Research And Development
DeferredTaxAssetDeferredExpenseCapitalizationResearchAndDevelopment
1450000
CY2023Q4 tkno Deferred Tax Asset Inventory Capitalization
DeferredTaxAssetInventoryCapitalization
428000
CY2022Q4 tkno Deferred Tax Asset Inventory Capitalization
DeferredTaxAssetInventoryCapitalization
0
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25152000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17046000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1231000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1131000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3600000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
4693000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
4402000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
5275000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9233000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
11099000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16838000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7170000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
919000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1223000
CY2023Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
9700000
CY2022Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
6700000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-36780000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-47468000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31819776
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31819776
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28083563
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28083563
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.69
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
22000
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
23000
CY2023 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
21000
CY2022 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
25000
CY2023 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
-23000
CY2022 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
-26000
CY2023Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
20000
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
22000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
42000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
86000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
42000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
8000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
136000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
42000
CY2023Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
300000

Files In Submission

Name View Source Status
0000950170-24-036624-index-headers.html Edgar Link pending
0000950170-24-036624-index.html Edgar Link pending
0000950170-24-036624.txt Edgar Link pending
0000950170-24-036624-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img237065587_0.jpg Edgar Link pending
img237065587_1.jpg Edgar Link pending
img237065587_2.jpg Edgar Link pending
img237065587_3.jpg Edgar Link pending
img237065587_4.jpg Edgar Link pending
img237065587_5.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tkno-20231231.htm Edgar Link pending
tkno-20231231.xsd Edgar Link pending
tkno-ex10_15.htm Edgar Link pending
tkno-ex10_38.htm Edgar Link pending
tkno-ex23_1.htm Edgar Link pending
tkno-ex31_1.htm Edgar Link pending
tkno-ex31_2.htm Edgar Link pending
tkno-ex32_1.htm Edgar Link pending
tkno-ex97.htm Edgar Link pending
tkno-20231231_htm.xml Edgar Link completed